Wedbush analyst Liana Moussatos reiterated a Buy rating on Verona Pharma (VRNA) today and set a price target of $25.00. The company’s shares closed last Friday at $5.87.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 3.0% and a 46.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verona Pharma with a $19.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.71 and a one-year low of $2.01. Currently, Verona Pharma has an average volume of 144.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
